Untangling the Drug–Drug Interaction Web in COVID-19 Outpatient Management – A GameOn! Challenge
This activity is supported by an educational grant from Pfizer Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Pfizer Inc.
Activity Description
Despite declining case numbers, coronavirus disease 2019 (COVID-19), a highly infectious respiratory illness that became a global pandemic resulting in deaths, is still a public health threat. Both the National Institutes of Health (NIH) and the Infectious Disease Society of America recommend initiating symptom management for all nonhospitalized adults with mild-to-moderate COVID-19. For adults who are at risk for progression to severe disease (eg, individuals with chronic lung diseases), specific recommendations are available and regularly updated. The time window after symptom onset that these agents are authorized or approved for vary; in general, treatment should be administered as soon as possible after symptom onset for maximum benefit. For patients who are at high risk of progressing to severe COVID-19, the NIH recommends—in order of preference—the oral antiviral ritonavir-boosted nirmatrelvir (nirmatrelvir/ritonavir), the intravenous antiviral remdesivir, and the oral antiviral molnupiravir. Clinicians are challenged on how to manage potential drug–drug interactions (DDIs) in the outpatient setting when using ritonavir-boosted nirmatrelvir. Because ritonavir is a strong cytochrome P450 3A4 inhibitor and a P-glycoprotein inhibitor, it may increase blood concentrations of certain concomitant medications and increase the potential for serious drug toxicities. Therefore, the Food and Drug Administration prescribing information for ritonavir-boosted nirmatrelvir includes a boxed warning for significant DDIs. Clinicians should consider both the potential benefits of treatment with ritonavir-boosted nirmatrelvir and the potential risks for related DDIs. This GameOn! Challenge will utilize a confidence-based platform designed to engage participants with a personalized, interprofessional approach to help them determine the most appropriate therapeutic plan for mitigating potential DDIs in outpatients with COVID-19.
Target Audience
The intended audience for this activity is US primary care providers, advanced practice providers, pharmacists, and other healthcare professionals involved in the management of patients with COVID-19.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Outline guidelines and clinician tools for the prevention and management of DDIs in outpatients with COVID-19.
- Determine the appropriate therapeutic regimen for patients with COVID-19, focusing on the mitigation of DDIs using interprofessional strategies.
Activity Chair
Rishi Desai, MD, MPH
Chief Medical Officer, Osmosis
Berkeley, CA
Faculty
Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP
Clinical Pharmacy Specialist – Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, MA
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Linda A. Giarraputo, BS, PA-C
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number is JA0006104-0000-24-037-H01-P, effective 1/31/2024. This is a knowledge-based activity, and there is no fee to attend.
Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.
Vindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 1/30/2025. PAs should only claim credit commensurate with the extent of their participation.
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.17 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24016486. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This enduring material is approved for 1 year from the date of original release, January 31, 2024, to January 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate, AAPA Category 1 CME credit certificate, Contact Hour Certificate, or CPE Statement of Credit.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Rishi Desai, MD, MPH
No relevant financial relationships to disclose.
Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP
Advisor: Melinta, Merck, Pfizer
Consultant: BD, Cidara, GSK
Speaker Contracted by Ineligible Company: Paratek
Independent Research Contractor: Merck
Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by getting in touch with our designated copyright agent (as outlined below). To do so, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (e.g., URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you either are the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com